ATE375792T1 - Verwendung von antikonvulsiven aminosäure zur behandlung von migräne - Google Patents

Verwendung von antikonvulsiven aminosäure zur behandlung von migräne

Info

Publication number
ATE375792T1
ATE375792T1 AT04021727T AT04021727T ATE375792T1 AT E375792 T1 ATE375792 T1 AT E375792T1 AT 04021727 T AT04021727 T AT 04021727T AT 04021727 T AT04021727 T AT 04021727T AT E375792 T1 ATE375792 T1 AT E375792T1
Authority
AT
Austria
Prior art keywords
lower alkyl
aryl
heterocyclic
unsubstituted
substituted
Prior art date
Application number
AT04021727T
Other languages
English (en)
Inventor
Robert H Harris
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of ATE375792T1 publication Critical patent/ATE375792T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT04021727T 2000-08-25 2001-08-24 Verwendung von antikonvulsiven aminosäure zur behandlung von migräne ATE375792T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22823000P 2000-08-25 2000-08-25

Publications (1)

Publication Number Publication Date
ATE375792T1 true ATE375792T1 (de) 2007-11-15

Family

ID=22856332

Family Applications (4)

Application Number Title Priority Date Filing Date
AT04021727T ATE375792T1 (de) 2000-08-25 2001-08-24 Verwendung von antikonvulsiven aminosäure zur behandlung von migräne
AT06012400T ATE476971T1 (de) 2000-08-25 2001-08-24 Aminosäure enthaltende antikonvulsiva zur behandlung von zwangsstörungen
AT04021728T ATE375793T1 (de) 2000-08-25 2001-08-24 Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen
AT01966230T ATE357227T1 (de) 2000-08-25 2001-08-24 Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz

Family Applications After (3)

Application Number Title Priority Date Filing Date
AT06012400T ATE476971T1 (de) 2000-08-25 2001-08-24 Aminosäure enthaltende antikonvulsiva zur behandlung von zwangsstörungen
AT04021728T ATE375793T1 (de) 2000-08-25 2001-08-24 Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen
AT01966230T ATE357227T1 (de) 2000-08-25 2001-08-24 Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz

Country Status (13)

Country Link
US (6) US6884910B2 (de)
EP (5) EP2210598B1 (de)
JP (2) JP4307068B2 (de)
AT (4) ATE375792T1 (de)
AU (6) AU2001286763C1 (de)
CA (2) CA2419285C (de)
CY (5) CY1107668T1 (de)
DE (4) DE60142806D1 (de)
DK (4) DK1486206T3 (de)
ES (5) ES2435000T3 (de)
LU (1) LU91512I2 (de)
PT (4) PT1695703E (de)
WO (1) WO2002015922A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2419285C (en) * 2000-08-25 2011-08-02 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants
ATE327744T1 (de) 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US20050233472A1 (en) * 2003-09-19 2005-10-20 Kao H P Spotting high density plate using a banded format
US7794987B2 (en) * 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
EP1537862A1 (de) * 2003-12-02 2005-06-08 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von zentralen neuropathische-Schmerzen
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (de) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
EP1604655A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EP1629839A1 (de) * 2004-08-27 2006-03-01 Schwarz Pharma Ag Verwendung von Peptidverbindungen zur Behandlung von Knochenkrebsschmerz sowie von Chemotherapie- oder Nukleosid-induziertem Schmerz
PL1781276T3 (pl) 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1920780A1 (de) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptidverbindungen zur Behandlung von Krankheiten mit erhöhter Erregbarkeit
EA019757B1 (ru) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
US7489198B1 (en) 2007-04-26 2009-02-10 Lockheed Martin Corporation Linear regulating switch
WO2011101863A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
RU2721401C2 (ru) * 2014-06-23 2020-05-19 Нортвестерн Юниверсити Способы лечения или облегчения мигрени
MX380311B (es) 2015-11-03 2025-03-12 Kimberly Clark Co Papel tisu con gran volumen y pocas pelusas.
BR112019021283B1 (pt) 2017-04-28 2023-02-28 Kimberly-Clark Worldwide, Inc Método para produzir um substrato, e, substrato
CN111247280B (zh) 2017-11-29 2021-08-17 金伯利-克拉克环球有限公司 具有改善的性能的纤维片材
MX2021000980A (es) 2018-07-25 2021-04-12 Kimberly Clark Co Proceso para fabricar no tejidos tridimensionales colocados en espuma.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795788A (nl) * 1972-02-22 1973-08-22 Akzo Nv Werkwijze ter bereiding van peptiden en peptide-derivaten en de toepassing hiervan
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
FR2546517B1 (fr) * 1983-05-24 1987-04-24 Panmedica Nouveaux dipeptides du -l-5-hydroxy-tryptophane, procedes pour leur preparation et medicaments les contenant
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5331089A (en) * 1988-03-25 1994-07-19 Merck Sharpe & Dohme, Ltd. Peptides useful as tachykinin agonists
US5178729A (en) * 1991-01-15 1993-01-12 James River Corporation Of Virginia High purity stratified tissue and method of making same
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
WO1994017794A1 (en) 1993-02-03 1994-08-18 Steven Andrew Jennings Blends of glycine derivatives and sugars
ES2154277T3 (es) * 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
US6348571B1 (en) * 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
JP3787605B2 (ja) * 1994-10-05 2006-06-21 ダーウィン・ディスカバリー・リミテッド ペプチジル化合物および金属プロテアーゼのインヒビターとしてのその治療的使用
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6514937B1 (en) * 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
DE69833858T2 (de) 1997-07-08 2007-02-22 Ono Pharmaceutical Co. Ltd. Aminosäurederivate
KR100522012B1 (ko) 1997-07-08 2005-10-18 오노 야꾸힝 고교 가부시키가이샤 아미노산 유도체
DE69808475T2 (de) 1997-07-15 2003-01-30 Research Corp. Technologies, Inc. Aminosäurederivate zur behandlung von schlaganfall
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6028102A (en) 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
EP1084704B1 (de) 1998-06-10 2006-03-29 Meiji Seika Kaisha Ltd. Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6399574B1 (en) * 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
CA2419285C (en) 2000-08-25 2011-08-02 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants
US6228825B1 (en) 2000-10-13 2001-05-08 Colgate Palmolive Company Automatic dishwashing cleaning system
ATE327744T1 (de) * 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz

Also Published As

Publication number Publication date
PT1486205E (pt) 2008-01-25
US20130316953A1 (en) 2013-11-28
ES2435000T3 (es) 2013-12-18
EP1365787B1 (de) 2007-03-21
CA2419285A1 (en) 2002-02-28
EP2210598A2 (de) 2010-07-28
CA2740815C (en) 2014-03-18
AU8676301A (en) 2002-03-04
EP1695703B1 (de) 2010-08-11
DK1695703T3 (da) 2010-10-25
AU2011202293A1 (en) 2011-06-09
LU91512I2 (fr) 2009-03-16
EP1486206B1 (de) 2007-10-17
PT1695703E (pt) 2010-11-16
ES2294414T3 (es) 2008-04-01
EP1695703A2 (de) 2006-08-30
CY2009002I2 (el) 2009-11-04
AU2007202336B9 (en) 2009-10-29
WO2002015922A2 (en) 2002-02-28
JP4307068B2 (ja) 2009-08-05
PT1486206E (pt) 2008-01-25
CA2740815A1 (en) 2002-02-28
DE60131033D1 (de) 2007-11-29
DE60127459D1 (de) 2007-05-03
JP2004506692A (ja) 2004-03-04
US8519183B2 (en) 2013-08-27
US20020086828A1 (en) 2002-07-04
US20100273716A1 (en) 2010-10-28
ATE375793T1 (de) 2007-11-15
DE60127459T2 (de) 2007-07-12
US7186859B2 (en) 2007-03-06
EP1695703A3 (de) 2006-12-13
DK1365787T3 (da) 2007-07-23
DE60142806D1 (de) 2010-09-23
CA2419285C (en) 2011-08-02
US20040097416A1 (en) 2004-05-20
DE60131032T2 (de) 2008-08-14
AU2009202362B2 (en) 2011-01-27
EP1486205A1 (de) 2004-12-15
JP2009108090A (ja) 2009-05-21
US7772427B2 (en) 2010-08-10
EP1365787A2 (de) 2003-12-03
DE60131033T2 (de) 2008-07-17
ES2294415T3 (es) 2008-04-01
ES2348646T3 (es) 2010-12-10
AU2001286763B2 (en) 2005-11-24
CY1107668T1 (el) 2010-07-28
AU2009202363B2 (en) 2011-02-17
US20040087508A1 (en) 2004-05-06
AU2011202293B2 (en) 2013-01-10
DK1486205T3 (da) 2008-02-18
CY1112349T1 (el) 2015-12-09
WO2002015922A3 (en) 2003-09-25
AU2009202362A1 (en) 2009-07-02
CY2009002I1 (el) 2009-11-04
US7148378B2 (en) 2006-12-12
ATE476971T1 (de) 2010-08-15
US20070142297A1 (en) 2007-06-21
DE60131032D1 (de) 2007-11-29
EP2210598B1 (de) 2013-09-18
AU2007202336A1 (en) 2007-06-14
DK1486206T3 (da) 2008-02-11
AU2007202336B2 (en) 2009-09-24
CY1107853T1 (el) 2013-06-19
AU2009202363A1 (en) 2009-07-02
CY1107852T1 (el) 2013-06-19
ATE357227T1 (de) 2007-04-15
EP2210598A3 (de) 2011-07-20
EP1486205B1 (de) 2007-10-17
AU2001286763C1 (en) 2006-03-02
JP5190334B2 (ja) 2013-04-24
EP1486206A1 (de) 2004-12-15
US6884910B2 (en) 2005-04-26
PT1365787E (pt) 2007-06-29
ES2281439T3 (es) 2007-10-01

Similar Documents

Publication Publication Date Title
DE60131032D1 (de) Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne
AR061743A1 (es) Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro
JP2009545521A5 (de)
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
AR061475A1 (es) Compuestos peptidicos para tratar status epilepticus refractario
JP2007530493A5 (de)
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
DE60119896D1 (de) Verwendung von pramipexol zur behandlung von tabak/nikotin abhängigkeit
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
JP2008501753A5 (de)
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
JP2008510758A5 (de)
DE60237100D1 (de) Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
EE200200632A (et) Glükokortikoidravimeid sisaldavad preparaadid bronhopulmonaalsete haiguste raviks
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
DE60142037D1 (de) Nasale verabreichung von metoclopramid zur behandlung der gastroparese
ATE260655T1 (de) Verwendung von stickstoffhaltigen aromatischen heterozyklusderivaten zur topischen behandlung von epithelerkrankungen
DE69924979D1 (de) Behandlung von chronischen schmerzen
ATE357916T1 (de) Tiagabine zur behandlung von diabetischer neuropathie
Brodda Contributions of Calcitonin gene-related peptide in ischemia, inflammation and nociception.
ATE288254T1 (de) Methode zur behandlung von schlaganfall
Ryu et al. The Literature Study on Medical treatments with acupuncture for
AR050097A1 (es) Uso de compuestos peptidicos para tratar dolor en neuropatia diabetica dolorosa
AR050196A1 (es) Uso de compuestos peptidicos para tratar esclerosis lateral amiotrofica

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1486205

Country of ref document: EP